Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin and Feladilimab in Relapsed/Refractory Multiple Myeloma (DREAMM5 Sub-study 2)
NCT07217119Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Nov 2019
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs)
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of belantamab mafodotin and feladilimab in multiple myeloma (MM), sponsored by GSK. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events at 281 weeks and 3 more. Started Nov 2019; status: active, not recruiting.
02
Drugs
belantamab mafodotinfeladilimab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07217119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07217119.